Founder & CEO

Dr. Shai Meretzki has over two decades of operational, management, and leadership experience in the life sciences industry. He has served as the CEO of Bonus Biogroup since its founding in 2008, leading the development of the Company’s proprietary regenerative medicine technologies. Prior to founding Bonus Biogroup, Dr. Meretzki founded Pluristem Therapeutics (now Pluri Inc. NASDAQ: PLUR), where he served as Chief Executive Officer and Chief Technology Officer. He holds a Ph.D. in Biotechnology from the Technion-Israel Institute of Technology, conducted in collaboration with the Weizmann Institute of Science.

VP of Finance

Meital Enbar, CPA, serves as Bonus Biogroup’s Vice President of Finance, overseeing financial planning, reporting, and compliance. Previously, she served as the controller at Bonus Biogroup.

CPA Enbar has 15 years of experience in financial management and corporate finance. She holds a degree in Accounting from the Academic Center for Law and Business in Ramat Gan and a certificate in Financial Management from the University of Haifa.

Chief Operations Officer

Dr. Dror Ben David serves as Bonus Biogroup’s Chief Operations Officer, overseeing all operational activities, including R&D, regulatory compliance, and manufacturing. Prior to that he served as the Company’s Vice President of Research and Development, leading the development of all product candidates. Prior to joining Bonus Biogroup, Dr. Ben David served as the manager of the Technion Musculoskeletal Tissue Engineering Lab. He holds a Ph.D. in Medical Sciences from the Technion-Israel Institute of Technology, specializing in regenerative medicine and adult stem cells.

VP Regulatory & Clinical Affairs

Dr. Vered Kivity serves as Bonus Biogroup’s Vice President of Regulatory & Clinical Affairs, overseeing regulatory strategy and clinical compliance. She has extensive experience in global regulatory and clinical affairs across pharma, biotech, and medical devices and has successfully led regulatory submissions worldwide. Dr. Kivity holds Ph.D. and MBA degrees from the Technion-Israel Institute of Technology.

VP Research & Development

Dr. Atara Novak serves as Bonus Biogroup’s Vice President of Research & Development, overseeing the advancement of investigational cell therapy and tissue engineering technologies. She holds a Ph.D. from the Technion Faculty of Medicine and has over 15 years of experience in stem cell biology. Prior to her role at Bonus Biogroup, she contributed to scientific research in cell therapy and tissue regeneration, with multiple publications in the field.

VP Quality Assurance

Dr. Corinne Chemouny serves as Bonus Biogroup’s Vice President of Quality Assurance, overseeing quality management and GMP compliance. She has over 20 years of experience in pharmaceutical manufacturing and regulatory compliance. Before joining Bonus Biogroup, she was the Pharmacist-in-Charge, leading quality initiatives at Taro Pharmaceuticals (a Sun Pharma Company). Dr. Chemouny holds a Pharm.D. degree and specializes in quality assurance and regulatory compliance for investigational therapies.

VP of Innovation & Corporate Development

Dr. Tomer Bronshtein serves as Bonus Biogroup’s Vice President of Innovation & Corporate Development, leading business development, investor relations, and strategic partnerships. He has over 15 years of experience in R&D and corporate strategy, with a focus on advancing investigational therapies. Dr. Bronshtein holds a Ph.D. in Biotechnology Engineering and has expertise in fostering collaborations between industry, healthcare providers, and investors.

Executive Chairman of the Board

Mr. Yossi Rauch serves as the Chairman of Bonus Biogroup’s Board of Directors since 2012. He previously served as Chief Economist and Manager of the Economics Department at Leumi PIA, Israel’s largest mutual fund company at the time. Previously, he served as the manager of the treasury department of Koor-Trade, a group of international trade companies, and a capital markets consultant in Israel and abroad.
Mr. Rauch holds an MBA in Finance & Accounting and Computers & Information Systems from Tel Aviv University and a BA in Economics and Business Administration from Bar-Ilan University.

Director

Mr. Gil Shapira serves on Bonus Biogroup’s board of directors since 2012. He is the Founder and CEO of ProPharma Ltd., a multidisciplinary design, construction, and consultancy company specializing in the pharmaceutical, biotechnology, and life science industries. Previously, he served for 18 years as CEO of A.D. Cleanroom Engineering Ltd., a company specializing in the design, construction, and validation of clean rooms. Mr. Shapira holds a B.Sc. in Industrial Management from the Polytechnic Brooklyn Institute, Brooklyn, New York. 

Director

Mr. Benjamin Shafir serves on Bonus Biogroup’s board of directors since 2020. He is a Partner at Yanai Group, where he has served since its inception. Mr. Shafir has over 30 years of experience and deep insight working with companies and organizations throughout the Israeli economy, including as a senior economist in large publicly traded companies. He specializes in business strategy and is experienced in leading complex economic processes in various areas, such as negotiation processes, mergers and acquisitions, enterprise valuation, and securing finance.
Mr. Shafir holds a BA in Economics and Psychology from the Hebrew University.

Director

Mr. Alon Ariel serves on Bonus Biogroup’s board of directors since 2020. He has served as the CEO of Milouot Ltd. since 2020, and between 2009 and 2020, he served as the CEO of Biological Industries Ltd.

Mr. Ariel previously served as a Business Manager of Beit Haemek Economic and Development Company 2000 Ltd. Mr. Ariel qualified as a Mechanical Engineer at Berufsakademie, Stuttgart, and received his BA in Chemistry and Management from the Open University of Israel and his degree in Plastics Engineering from the Center for Engineering and Technology. He also graduated from Tzor College, the Tzor School for key posts in industry, and the Tefen Industrial Park.

Director

Ms. Margalit Assayag has served on Bonus Biogroup’s board of directors since 2020. Mrs. Assayag served as Chief Executive Officer of a non-profit social learning project, “Password for Every Student,” since 2009 and previously served as a member of the National Petroleum Council at Israel’s Ministry of Energy. She has over 30 years of experience in management and command in key positions at the decision-making level, with an emphasis on the Israeli Defense Forces and third-sector organizations. Mrs. Assayag holds a B.A. degree in Economics and Criminology from Bar-Ilan University and an MBA degree in Business Administration from Ben-Gurion University and is a graduate of the University of Bar-Ilan’s Directors Course.

MD, Ph.D

Prof. Nimrod Rozen is a renowned Israeli orthopedic surgeon and researcher with over two decades of expertise in orthopedic trauma. He served as the Head of the Orthopedic and Rehabilitation Division at Ha’Emek Medical Center from 2006 until his retirement in 2025. He is the former President of the Israeli Orthopedic Association and the Founder of the Institute for Bone Repair at Rambam Health Care Campus. Prof. Rozen currently serves as the Chief Orthopedist of Clalit Health Services and is a Clinical Associate Professor at the Technion–Israel Institute of Technology. He has published over 90 scientific papers, with a research focus on complex and non-healing fractures.

 DMD

Dr. Ephraim Tzur is an oral and maxillofacial surgeon with expertise in implant surgery and craniomaxillofacial rehabilitation. He previously served as Director of the Oral & Maxillofacial Surgery Unit at Assaf Harofeh Medical Center. With over 30 years of experience, Dr. Tzur specializes in the reconstruction and rehabilitation of oral and facial structures.

Mr. Malcolm I. Hoenlein is the former Executive Vice Chairman/CEO of the Conference of Presidents of Major American Jewish Organizations, a position he held until 2022. He has held leadership roles in policy and international relations, including as a Middle East specialist at the Foreign Policy Research Institute. Mr. Hoenlein holds a BA from Temple University and completed doctoral coursework at the University of Pennsylvania.